CDT Leverages AI to Match 1,700 Rare Disease Signatures, Targets Orphan Drug Partnerships
CDT completed AI-driven signature mapping of its asset portfolio, including AZD1656 and AZD5658, against Sarborg’s database of 1,700 rare disease signatures and found significant matches in immunology, oncology, infectious disease, pediatric and ophthalmology indications. The company plans preclinical validation to build out-licensing packages using orphan drug incentives and market exclusivity.
1. AI-Driven Signature Mapping
CDT employed Sarborg’s proprietary AI Signature Agent platform to evaluate its solid-form patent portfolio and AstraZeneca-licensed compounds AZD1656 and AZD5658 against a database of approximately 1,700 rare disease signatures, enabling data-driven identification of potential orphan indications.
2. Identified Rare Disease Matches
The analysis generated statistically significant matches across multiple therapeutic areas—including immunology, oncology, infectious disease, pediatric and ophthalmology—highlighting differentiated opportunities in underserved and orphan disease settings.
3. Preclinical Validation and Out-Licensing Strategy
CDT intends to conduct targeted preclinical validation, including in vivo studies, to substantiate signature findings and assemble comprehensive out-licensing packages that leverage expedited regulatory pathways, orphan drug incentives and enhanced market exclusivity.